Introduction
============

Posterior polymorphous corneal dystrophy (PPCD; OMIM [122000](http://www.molvis.org/molvis/external.cgi?omim=122000), [609140](http://www.molvis.org/molvis/external.cgi?omim=609140), and [609141](http://www.molvis.org/molvis/external.cgi?omim=609141)) is an autosomal dominant endothelial corneal dystrophy characterized by vesicular lesions and epithelial-like changes of the corneal endothelium. PPCD shows variable expressivity \[[@r1],[@r2]\] and while most cases are mild; severe cases require corneal transplantation (about 11%) \[[@r3]\]. PPCD is an important indication of penetrating keratoplasty for congenital corneal opacities and a significant risk factor for the development of glaucoma \[[@r4],[@r5]\].

PPCD is genetically heterogeneous with linkage reported to three different loci \[[@r6]-[@r8]\] and evidence for further locus heterogeneity \[[@r9]\]. PPCD1 (OMIM [122000](http://www.molvis.org/molvis/external.cgi?omim=122000)) was mapped to a 30 cM pericentromeric region on chromosome 20 (between D20S98 and D20S108) using a large three generation family \[[@r6]\]. This interval includes the 2.7 cM region for autosomal dominant congenital hereditary endothelial dystrophy (CHED1; OMIM [121700](http://www.molvis.org/molvis/external.cgi?omim=121700)) \[[@r10]\], suggesting that the two conditions might be allelic variants.

*VSX1*, a paired-like homeobox transcription factor in the PPCD1 disease interval, is an attractive positional and functional candidate gene. Different groups have reported mutations involving functional domains of *VSX1* in patients affected with PPCD \[[@r11],[@r12]\], keratoconus \[[@r11],[@r13]\], or a combination of both phenotypes \[[@r11],[@r14]\]. However, unresolved issues remain concerning the pathogenic role of *VSX1* in PPCD. This gene was not shown to be expressed in adult human cornea \[[@r11],[@r15],[@r16]\]. Mice with null alleles do not show any corneal abnormalities \[[@r17]\]. In addition, no mutations were detected in the family used for mapping the PPCD1 locus (Z~max~=5.54 at θ=0 for marker D20S45) \[[@r6],[@r11]\].

Failure to detect a pathological sequence variant by mutational analysis of the coding sequence (exons 1--5) of *VSX1*, a key candidate gene, in the original PPCD1-linked families \[[@r6],[@r11]\] prompted our group to characterize expression profile and regulatory elements of this gene to identify novel *VSX1* genomic sequences for analysis. We addressed the controversy over corneal expression of *VSX1* by performing a temporal expression analysis in human samples that showed perinatal expression of this gene in human cornea. To address the genetic basis of disease in PPCD1-linked families, we further investigated the pathogenic role of *VSX1*, considering different possible mutation mechanisms involving previously uncharacterized transcript variants or regulatory elements. Finally, further mapping of the disease interval in PPCD1-linked families, with or without a *VSX1* mutation, suggests genetic heterogeneity at the PPCD1 locus.

Methods
=======

Human subjects identification
-----------------------------

The project was approved by The Hospital for Sick Children Research Ethics Board and was conducted in accordance with the tenets of the Declaration of Helsinki. All participating patients signed an informed consent. Patients were recruited through the ocular genetics clinic of the Hospital for Sick Children and by international collaborators.

Three PPCD affected families with evidence of linkage to PPCD1 were included in the study. The original mapping study of PPCD1 was conducted on family 1 \[[@r6]\]. Family 2 was also linked to PPCD1 (unpublished data). Family 3 was the first PPCD affected family with a *VSX1* mutation identified (G160D) \[[@r11]\]. No *VSX1* mutation had been identified in families 1 or 2 \[[@r11]\].

RNA extraction
--------------

Human eyes or corneas of different ages (12 weeks of gestation to 64 years) were collected within 24 h postmortem from the Eye Bank of Canada (Ontario Division) or a local abortion clinic and preserved in RNALater^TM^ (Ambion, Austin, TX). After rapid dissection, total RNA was isolated using TRIzol® reagent (Invitrogen, Burlington, Canada). DNA contamination was removed by RNase-free DNase I treatment (Roche, Laval, Canada).

Real-time semi-quantitative RT--PCR
-----------------------------------

One μg of total RNA was reverse transcribed (SuperScript^TM^ II First-Strand Synthesis, Invitrogen) using random hexamers. Melanin inhibition of RT--PCR was reversed by adding 20 μg of BSA (New England Biolabs, Ipswich, MA) to the reaction after primary denaturation \[[@r18]\].

Real-time PCR was conducted according to standard guidelines (Brilliant® SYBR® Green qPCR Master Mix, Stratagene, La Jolla, CA; Abi Prism® 7500-HT, Applied Biosystems, Foster City, CA). Dissociation curve analysis of amplification products was performed to confirm presence of a single product. To maintain consistency, baseline and threshold values were set automatically by the data analysis software (SDS v2.1, Applied Biosystems). To standardize the amount of cDNA in each reaction, an endogenous reference gene was used as internal control. Relative expressions were calculated based on the C~t~ values according to models previously described \[[@r19]\].

Rapid amplification of cDNA ends (RACE)
---------------------------------------

3′ RACE was performed on 1 μg of total retinal RNA (extracted from adult human retina) using FirstChoice® RLM-RACE kit (Ambion) according to standard guidelines \[[@r20],[@r21]\]. Primers used are shown in [Table 1](#t1){ref-type="table"} (PCR conditions are available upon request). Final PCR products were electrophoresed on 2% sieving agarose gels. All major visible DNA bands were gel purified (MinElute® or QIAquick Gel Extraction, Qiagen, Mississauga, Canada), ligated into a T-vector (pGEM® T-Easy Vector, Promega, Madison, WI) and transformed into Competent E.coli (Subcloning Efficiency^TM^ DH5α^TM^, Invitrogen). Plasmid DNA was extracted from positive clones (QIAprep® Miniprep, Qiagen). The presence of expected inserts was confirmed by enzymatic digestion (*Eco*RI or *Eag*I, New England Biolabs) before bidirectional sequencing using T7 and SP6 primers. Sequence files for each clone were then assembled into a single FASTA file ([CAP3](http://pbil.univ-lyon1.fr/cap3.php) software provided in the public domain by PBIL) \[[@r22]\] and aligned against the genomic sequence ([NT_011387](http://www.molvis.org/molvis/external.cgi?gbdna=NT_011387)) using the mRNA-to-genomic alignment program [Spidey](http://www.ncbi.nlm.nih.gov/spidey/index.html) (provided in the public domain by NCBI) \[[@r23]\].

###### Sequence of oligonucleotide primers.

  **Category**                **Primer Name**               **Sequence**
  --------------------------- ----------------------------- -----------------------
  3′RACE                      Outer g.s.\* Primer A (3OA)   ATGAGGACAGCCAGTCTGAA
  Inner g.s. Primer A (3IA)   ACCTTGGGCAAGAGGAAGAA          
  Outer g.s. Primer B (3OB)   ATGGCCGAGTACGGGCTGT           
  Inner g.s. Primer B (3IB)   CAGACTCCGTGCTCAACTCC          
                                                            
  Realtime RT--PCR            GAPDH fwd                     CAGGGATGATGTTCTGGAGAG
  GAPDH rev                   CTGCACCACCAACTGCTTAG          
  VSX1 fwd                    GGGCAGATAATATACTCCACAAAG      
  VSX1 rev                    CATTTCTCGGGCATACACATC         
                                                            
  VSX1 regulatory elements    R1-R2 fwd                     GCCCTGCAAAGTGGGTCT
  R1-R2 rev                   CTCACAGCAGGTCCAACCTC          
  R3--1 fwd                   TGCTAAAGAGCCGCAGATTG          
  R3--1 rev                   GATGCACTTGTCTCCTCGTG          
  R3--2 fwd                   CTCTTCCCAACTGAAAAATGC         
  R3--2 rev                   TCTGAAGGAGAGTATTTGATTTCC      
  R4 fwd                      GAAGCACAAGACAGGGAAGG          
  R4 rev                      AAGCTGAGGATGTGTTCCTG          
  R5 fwd                      ACCCAAAACGTCAGGACTTC          
  R5 rev                      AGCTGTGTTCTTCCCATGC           
  R6 fwd                      ATGGGCAGGATACTGTGGAG          
  R6 rev                      TGGAAGGAACTTTGGACCTC          

Sequences of other primers will be available upon request. \*g.s.: gene specific.

Whole genome amplification
--------------------------

Genomic DNA was extracted from peripheral blood or buccal swabs \[[@r24],[@r25]\]. In the case of index families, DNA was amplified before application in downstream assays using a ϕ29 polymerase based system (GenomiPhi^TM^, Amersham Biosciences, Piscataway, NJ) \[[@r26]\]. Whole genome amplification methods based on multiple displacement provide a balanced representation of genome suitable for genotyping and sequencing \[[@r27],[@r28]\].

DNA sequencing
--------------

DNA fragments of interest were PCR-amplified \[[@r21],[@r29]\] and purified (QIAquick PCR Purification, Qiagen) before cycle sequencing and sequence analysis as described elsewhere \[[@r30]\].

Short tandem repeat polymorphism (STRP) genotyping
--------------------------------------------------

DNA (20--50 ng) from selected individuals were PCR-amplified, denatured, electrophoresed and detected on an automated sequencer (ALF^TM^, Pharmacia Biotech AB, Uppsala, Sweden). Genotypes were determined by software analysis (Fragment Manager v1.1, Pharmacia LKB Biotechnology, Uppsala, Sweden).

Results
=======

Temporal expression profile of human *VSX1*
-------------------------------------------

To elucidate the temporal expression profile of *VSX1* in the cornea, semi-quantitative RT--PCR was performed on a panel of human eye tissues (adult, neonatal, and fetal). To select the least variable internal control gene, a validation strategy based on the geometric average of multiple control genes was used \[[@r31]\]. Of the housekeeping genes tested (*ACTB*, *GAPDH,* and *Cyclophilin A*), *GAPDH* was selected as the reference gene since it showed the lowest variation (geometric average of 1.401). The experiment was repeated three times in triplicate with each cDNA sample. [Figure 1](#f1){ref-type="fig"} shows the expression profile of *VSX1* based on relative comparative fold to the housekeeping gene. Real-time PCR on human ocular tissues confirmed expression of *VSX1* in neonatal but not in adult cornea. The highest expression was in retina and in the neonatal period. Lens and neonatal cornea show the lowest levels of expression. No expression was detected in the sclera or in the adult and early fetal cornea (less than or equal to 20 weeks).

![Relative expression of *VSX1* in a panel of eye tissues of differnet ages. Each bar represents the relative expression of *VSX1* normalized to *GAPDH* in a different tissue/age; mean±SD (Sc: sclera, Co: cornea, Ir: iris, CB: ciliary body, Len: lens, Cho: choroid, Ret: retina, ONH: optic nerve head). Numbers above each bar are the average level of expression relative to neonatal retina obtained from triplicates of the experiment. Numbers on the x-axis are the age of donor individuals (w: fetal week, y: year, m: month, d: day). Data for corneal samples is shown expanded in the inset.](mv-v14-71-f1){#f1}

Characterizing *VSX1* transcript variants
-----------------------------------------

EST alignments available in the UCSC genome browser and exon predictions based on EST clustering, such as [ECgene](http://genome.ewha.ac.kr/ECgene/) v1.2 and [AceView](http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly), provided evidence of novel exons downstream to *VSX1*. This was confirmed by RT--PCR on human adult retinal RNA using primers in predicted exons that produced PCR products of expected sizes.

To identify different mRNA classes transcribed from the *VSX1* gene, a 3′RACE experiment was performed on human adult retinal total RNA. Nested PCR using gene specific primers ([Table 1](#t1){ref-type="table"}, 3OA and 3IA) consistently yielded six polyadenylated products on gel electrophoresis ([Figure 2](#f2){ref-type="fig"}). Duplication of the experiment using another set of primers ([Table 1](#t1){ref-type="table"}, 3OB and 3IB) produced similar results (data not shown). Sequence analysis of the 3′RACE product clones consistently revealed two novel downstream exons for *VSX1*, exon 6 and exon 7. Exon 6, 108 bp in length, is located at position 24993279--24993172 on genomic contig [NT_011387](http://www.molvis.org/molvis/external.cgi?gbdna=NT_011387). Exon 7 spans 535 bp of genomic DNA at position 24992119--24992654 ([NT_011387](http://www.molvis.org/molvis/external.cgi?gbdna=NT_011387)). These two exons were mainly non-coding, not highly conserved and alternatively spliced in different *VSX1* transcripts. Including these novel exons, the *VSX1* gene now spans 10.65 kb of genomic DNA (former genomic size 6.7 kb).

![Photograph of ethidium bromide stained 3′RACE products electrophoresed on a 2% sieving agarose gel. Numbers on the left show the sizes of molecular marker (M) bands in bp. Numbers on the right correspond to different *VSX1* transcript variants.](mv-v14-71-f2){#f2}

The full cDNA sequence for each of the transcript variants was deposited in GenBank ([DQ854807](http://www.molvis.org/molvis/external.cgi?gbdna=DQ854807) to [DQ854812](http://www.molvis.org/molvis/external.cgi?gbdna=DQ854812)). Sequence of the 5′end of transcripts (5′UTR, exon 1 and 5′ end of exon 2) was obtained using previously reported *VSX1* sequence (GenBank [NM_014588](http://www.molvis.org/molvis/external.cgi?gbdna=NM_014588)). Transcript variants 1 and 2 (GenBank [NM_014588](http://www.molvis.org/molvis/external.cgi?gbdna=NM_014588) and [NM_199425](http://www.molvis.org/molvis/external.cgi?gbdna=NM_199425)) were previously described ([Figure 3A](#f3){ref-type="fig"}) \[[@r32]\]. Transcripts 3 to 6 are novel ([Figure 3B](#f3){ref-type="fig"}).

![The mRNAs transcribed from the human *VSX1* gene. **A**: Previously described; **B**: novel transcript variants. Exons are numbered from 1 to 7. Black boxes indicate coding sequences; thin broken lines indicate spliced intronic sequences; gray boxes indicate untranslated regions. Numbers on the right show the length of each transcript variant as determined from the +1 position.](mv-v14-71-f3){#f3}

Transcript 1 has the longest ORF, encoding a 365 residue protein (38.43 kDa) containing homeodomain (HD), CVC (*Chx10*, *Vsx1* and *ceh-10*) and RV (*RINX* and *Vsx1*) domains and additional motifs previously described \[[@r32]\]. Other transcripts result in truncated protein products lacking RV domain, part or the whole CVC domain and sometimes the carboxyl end of the HD. The most carboxyl ends of these truncated polypeptides show no significant homology ([Figure 4](#f4){ref-type="fig"}) to any known protein domains ([Pfam](http://www.sanger.ac.uk/Software/Pfam/) software, provided in the public domain by the Sanger institute).

![Schematic representation of VSX1 protein isoforms. Conserved domains of VSX1 and the numbered amino acid residues comprising each domain are indicated. The numbers on the right show total length of each isoform. N and C are amino and carboxyl termini of the isoforms. (NLS: nuclear localization signal; CVC: Chx10, Vsx1, ceh-10 domain; RV: RINX, Vsx1)](mv-v14-71-f4){#f4}

Predicting *cis-*regulatory modules
-----------------------------------

To identify conserved non-genic sequences (CNGs) potentially related to *VSX1*, 110 kb of genomic sequence (50 kb upstream and downstream of the gene; chr20:24,950,120--25,060,767; UCSC hg17) was compared with orthologous sequences in 9 non-human vertebrates (dog, mouse, rat, opossum, chicken, frog, *Tetraodone*, zebrafish and *Fugu*). Publicly available, gapped and ungapped alignments available at [Vista](http://genome.lbl.gov/vista/index.shtml) genome (provided in the public domain by the Genomics Division of Lawrence Berkeley National Laboratory) and [ECR](http://ecrbrowser.dcode.org/) (provided in the public domain by the Dcode.org Comparative Genomics Center) browsers were used \[[@r33]-[@r35]\]. The analysis was performed under the established parameters for CNGs (70% identity in 100 bp window) \[[@r36],[@r37]\]. These criteria revealed five upstream and one downstream evolutionary conserved regions (ECRs) with conservation between the human reference and multiple (at least three) other non-primate vertebrate lineages. Other ECRs in this region physically overlap exons of *VSX1* or the adjacent gene (*ACAS2L*). These six ECRs (5+1) are most likely non-coding as no corresponding spliced ESTs were detected ([Table 2](#t2){ref-type="table"}). This approach for identification of ECRs has been validated and established for identifying sequences with slower evolution than the average neutral rate \[[@r36]\].

###### Amplicons containing ECRs in the vicinity of *VSX1*.

  **ECR**   **Approximate size (bp)**   **ECR start position**   **ECR end position**
  --------- --------------------------- ------------------------ ----------------------
  R1        256                         25,012,020               25,012,275
  R2        46                          25,013,495               25,013,640
  R3        2700                        25,027,750               25,030,450
  R4        410                         25,045,600               25,046,010
  R5        700                         25,057,481               25,058,179
  R6        2220 (two elements)         24,982,900               24,985,120

Sequence positions refer to the May 2004 release of human reference sequence (NCBI build 35).

Predicted ECRs consistently overlapped conserved transcription factor binding site (TFBS) clusters predicted by rVista 2.0 program (pre-computed annotation of ECR browser) \[[@r38]\]. Overlap with TFBSs supports the functional role of predicted ECRs. The conserved nature of these TFBS clusters suggests these could be *cis*-regulatory modules (CRMs) regulating *VSX1* expression.

Mutation analysis of *VSX1* and related ECRs
--------------------------------------------

Mutation analysis of *VSX1* in the family used for mapping PPCD1 locus (Family 1) as well as 2 other families suggested to be linked to PPCD1, included the five known exons, the two novel exons 6 and 7, and the end part of exon 3 specific to transcript variant 2 (exon 3b in [Figure 3A](#f3){ref-type="fig"}) was carried out. No change was identified in selected individuals sequenced from these families.

We expanded our mutation analysis to include the ECRs around *VSX1*. Mutational analysis of amplicons containing the six identified ECRs (see above) failed to show mutations in Families 1 and 2. Three previously described SNPs were observed in Family 1. rs6050337 with a minor allele frequency of 0.267 (dbSNP) was identified in R4 (heterozygous). Minor alleles of two other SNPs ([rs2224072](http://www.molvis.org/molvis/external.cgi?snp=rs2224072) and [rs4141461](http://www.molvis.org/molvis/external.cgi?snp=rs4141461)) were observed as homozygous in R3. None of the identified SNPs cosegregate with the disease status.

Fine mapping of the PPCD1 critical region
-----------------------------------------

No *VSX1* disease-causing mutations were found in the two PPCD families (Families 1 and 2) initially used for mapping the disease to chromosome 20. The 20 cM critical disease interval described by Héon et al. \[[@r6]\] also included *ID1*, a developmentally important dominant negative helix--loop--helix protein which did not show any mutation of the coding sequence in these families (unpublished data).

Therefore, mapping of the disease interval was refined for families 1 and 3 ([Figure 5](#f5){ref-type="fig"} and [Figure 6](#f6){ref-type="fig"}). Family 2 (not shown) could not be used for narrowing down the interval due to the poor family structure (DNA available from 2 affected individuals). In Family 1 ([Figure 5](#f5){ref-type="fig"}) recombination events narrowed down the critical interval to 16.44 cM (about 21.55 Mb). Further genotyping of family 3 (even though known to carry two *VSX1* changes; [Figure 6](#f6){ref-type="fig"}) \[[@r11]\] narrowed the disease interval to 6.57 cM (about 14.8 Mb).

![Pedigree structure of family 1 and its haplotype analysis at PPCD1 locus. This family was originally used to map PPCD to the chromosome 20 locus \[[@r6]\]. No *VSX1* mutation has been identified in this family. Marker names are shown on the right. Genotypes of each individual are shown as numbers underneath the individual\'s symbol. Dark bars represent the inferred disease haplotype with recombinations of parental chromosome shown.](mv-v14-71-f5){#f5}

![Haplotype analysis of family 3 at PPCD1 locus. The family has been fully described elsewhere \[[@r11]\] with mutations observed in *VSX1* coding sequence. Marker names are shown on the right. Genotypes of each individual are shown as numbers underneath the individual\'s symbol. Dark bars represent the inferred disease haplotype with recombinations of parental chromosome shown.](mv-v14-71-f6){#f6}

There was no evidence of haplotype sharing between these families (data not shown). [Figure 7](#f7){ref-type="fig"} schematically summarizes the disease intervals for the PPCD1 families described to date including our recent data. These data suggest heterogeneity at PPCD1 locus by breaking it to two intervals. The disease interval for family 3, known to have a *VSX1* mutation, is definitely distinct from the CHED1-PPCD1 overlap interval described in Czech families (see discussion) \[[@r39]\].

![Ideogram of chromosome 20 showing PPCD1 minimal disease interval in different families. Bars on the left represent the disease intervals for PPCD1 and CHED1 as originally described \[[@r6],[@r10]\]. Bars on the right show the refinements made in our study. Family 1 is the family used for mapping the locus (further refinement). Family 3 is the family described by Heon et al. \[[@r11]\] with a known *VSX1* mutation. Cz1 and Cz2 represent Czech families described by Gwilliam et al. \[[@r39]\].](mv-v14-71-f7){#f7}

Mutation analysis of candidate genes from PPCD1-CHED1 interval
--------------------------------------------------------------

Genes in the PPCD1-CHED1 overlap interval were prioritized based on corneal expression and function. Available corneal EST and SAGE libraries were used as the initial evidence of corneal expression. Expression was further confirmed by RT--PCR on human corneal RNA \[[@r40]-[@r43]\]. The strongest three candidate genes included *RBBP9, ZNF133,* and *SLC24A3* (see discussion). We analyzed the coding sequence of these genes in individuals from both families (1 and 2) which did not reveal any mutation. Sequence analysis included the first seven exons of *SLC24A3* located in the PPCD1-CHED1 overlap interval.

Discussion
==========

Our study is the first documentation (and assessment) of *VSX1* expression in neonatal human cornea. This observation is significant since the role of *VSX1* as a candidate gene was questioned, partly due to its expression profile \[[@r44]\]. *VSX1* expression was proposed to be exclusive to a subset of inner nuclear layer cells of retina and absent from the adult human or developing mouse cornea \[[@r11],[@r15],[@r32]\]. The results from our study supported the findings of two recent murine studies \[[@r16],[@r45]\] showing corneal expression of *VSX1*.The *VSX1* expression seems to be restricted to the perinatal period, which is consistent with the current hypothesis that PPCD-related abiotrophy begins during perinatal endothelial differentiation \[[@r46]\]. Electron microscopic studies on Descemet\'s membrane of PPCD cases, provides evidence that the pathology arises at gestation or shortly after birth \[[@r46],[@r47]\].

We showed alternative splicing of *VSX1* and characterized six different transcript variants for this gene. Five of the six transcript variants identified encode truncated proteins. Isoforms 2, 4, and 6 are not expected to bind the DNA efficiently due to the lack of recognition helix of HD. Isoforms 3 and 6, which retain most of the DNA binding domains, should have significant DNA binding activity. Alternatively spliced transcripts encoding truncated isoforms have been described in several homeodomain genes \[[@r48]-[@r51]\]. The functional significance of *VSX1* truncated isoforms remains unclear. However, since all of these isoforms retain the proline-rich and acidic domains for transcriptional activation, they may modulate the transcriptional activity of the full-length protein by competing for co-activators or co-repressors. Another possibility is having independent developmental functions, through a mechanism other than DNA binding \[[@r50]\].

A thorough mutation analysis of novel *VSX1* exons and ECRs in the vicinity of the gene in the original PPCD1 family failed to reveal any disease causing mutation. It seems that *VSX1* plays a pathogenic role only in a subgroup of PPCD1 mapped families. *VSX1* changes observed in Family 3 were considered biologically significant (conservation and segregation with the disease status) \[[@r11]\] and convincing *VSX1* mutations have been reported in PPCD families from other groups \[[@r12]-[@r14]\]. Nonetheless, not identifying a disease-associated mutation in *VSX1\'s* genomic sequence, different transcript variants and regulatory elements, in some chromosome 20-linked PPCD families (including family 1) suggests that another gene may be involved \[[@r11],[@r39]\].

Fine mapping of the disease interval in the family with an identified *VSX1* mutation (Family 3) showed that the smallest disease interval in this family is distinct from one of the reported Czech families \[[@r39]\], suggesting genetic heterogeneity of the original PPCD1 locus ([Figure 7](#f7){ref-type="fig"}).

Autosomal dominant CHED (CHED1) and PPCD share several clinical, histopathologic, and immunohistochemical features, which suggest that these two conditions could be allelic variants. Overlap of PPCD1 and CHED1 loci (especially in the Cz2 family) is consistent with this concept of clinical heterogeneity \[[@r10],[@r52]\]. This suggests that CHED1 may be a locus for a second PPCD gene on chromosome 20.

No other human ocular phenotype maps to the new PPCD1-CHED1 minimal disease interval (20p11.23-p12.1; [OMIM](http://www.ncbi.nlm.nih.gov/omim), provided in the public domain by NCBI). Three ocular phenotypes (corneal disease-1, corneal disease 1- 2 Jackson, and blind-sterile) map to the syntenic region in the mouse genome on the distal part of chromosome 2 ([Mouse Genome Informatics](http://www.informatics.jax.org/), provided in the public domain by the Jackson Laboratory). None of these conditions have direct relevance to corneal endothelium \[[@r53]-[@r55]\]. This interval contains more than 20 genes, some of which are interesting candidate genes based on expression and functional evidences.

We excluded the coding sequence of three additional candidate genes in our families. *RBBP9* (retinoblastoma binding protein 9), with high expression in corneal endothelium \[[@r40]\], has been shown to be important in the transformation process via its capacity to confer resistance to the growth-inhibitory effects of TGF-β1 \[[@r56]\]. PPCD occurs in consequence of metaplasia from a non-proliferating endothelium to an expanding epithelium. Interestingly, there is compelling evidence that the arrest of normal endothelium in the G1-phase of cell cycle is partly regulated by TGF-β (both β1 and β2) \[[@r57]\] which is known to be expressed by cultured human endothelial cells \[[@r58]-[@r60]\] and in aqueous humor \[[@r61]-[@r63]\]. *ZNF133,* a transcriptional repressor containing KRAB box and zinc finger domains \[[@r64],[@r65]\], is a strong candidate gene with corneal expression \[[@r41],[@r43],[@r66],[@r67]\]; since another zinc finger protein (*TCF8*) has been associated with PPCD \[[@r45]\]. *SLC24A3* (solute carrier family 24 member 3) shows corneal expression \[[@r68]\]. The interest in this K^+^-dependent Na^+^/Ca^2+^ exchangers is related to the recent association of another solute carrier (*SLC4A11*) with autosomal recessive CHED \[[@r69],[@r70]\].

Endothelial corneal dystrophies are significant causes of visual impairment that would benefit from further molecular characterization. However, elucidation of the genetic basis of chromosome 20-related PPCD will require larger patient cohorts to fully evaluate the role of the regulatory elements and isoforms of *VSX1* as well as to validate the role of other mutational events or disease-associated genes.
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